Published in Curr Med Res Opin on January 01, 2002
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet (2010) 18.09
The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet (2012) 17.29
Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One (2012) 1.93
The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. Eur Heart J (2015) 1.83
Bias in observational studies of prevalent users: lessons for comparative effectiveness research from a meta-analysis of statins. Am J Epidemiol (2012) 1.76
Relation of different measures of low-density lipoprotein cholesterol to risk of coronary artery disease and death in a meta-regression analysis of large-scale trials of statin therapy. Am J Cardiol (2010) 1.53
The exclusion of patients with chronic kidney disease from clinical trials in coronary artery disease. Kidney Int (2006) 1.47
The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol (2004) 1.45
Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. Br J Clin Pharmacol (2004) 1.44
Effectiveness of statins for secondary prevention in elderly patients after acute myocardial infarction: an evaluation of class effect. CMAJ (2005) 1.43
Dyslipidemia in primary care--prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS). Cardiovasc Diabetol (2008) 1.14
Interventions to improve adherence to lipid lowering medication. Cochrane Database Syst Rev (2004) 1.12
Statins and cardiovascular outcomes in elderly and younger patients with coronary artery disease: a post hoc analysis of the GREACE study. Arch Med Sci (2013) 1.01
Stroke prevention: modifying risk factors. Ther Adv Cardiovasc Dis (2008) 0.99
Nitropravastatin stimulates reparative neovascularisation and improves recovery from limb Ischaemia in type-1 diabetic mice. Br J Pharmacol (2007) 0.98
Do hypertensive patients with average cholesterol levels benefit from atorvastatin therapy? CMAJ (2003) 0.94
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver disease. World J Hepatol (2013) 0.92
Change in prevalence of chronic kidney disease in England over time: comparison of nationally representative cross-sectional surveys from 2003 to 2010. BMJ Open (2014) 0.89
Prospective analysis of association between use of statins and melanoma risk in the Women's Health Initiative. Cancer (2012) 0.87
Statins in the treatment of chronic heart failure: a systematic review. PLoS Med (2006) 0.85
Statins for the prevention of stroke: a meta-analysis of randomized controlled trials. PLoS One (2014) 0.82
Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. Open Cardiovasc Med J (2007) 0.82
Impact of treatment with rosuvastatin and atorvastatin on cardiovascular outcomes: evidence from the Archimedes-simulated clinical trials. Clinicoecon Outcomes Res (2015) 0.82
Intraocular Pressure: Does it Measure Up? Open Ophthalmol J (2009) 0.81
Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol (2015) 0.81
Lipid-lowering therapies and achievement of LDL-cholesterol targets. Arch Med Sci (2012) 0.81
The GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Curr Med Res Opin (2002) 0.81
Lipid lowering therapy in type 2 diabetes. Wien Med Wochenschr (2011) 0.80
Does combination therapy with statins and fibrates prevent cardiovascular disease in diabetic patients with atherogenic mixed dyslipidemia? Rev Diabet Stud (2013) 0.80
Clinical neuroprotective drugs for treatment and prevention of stroke. Int J Mol Sci (2012) 0.79
Reassessing the benefits of statins in the prevention of cardiovascular disease in diabetic patients--a systematic review and meta-analysis. Rev Diabet Stud (2013) 0.79
The clinical benefit of implementing guidelines in cardiovascular disease prevention in real world settings. Arch Med Sci (2012) 0.79
Cholesterol Contributes to Diabetic Nephropathy through SCAP-SREBP-2 Pathway. Int J Endocrinol (2013) 0.79
Problems and possible solutions for therapy with statins. Int J Angiol (2013) 0.78
Rosuvastatin versus atorvastatin in achieving lipid goals in patients at high risk for cardiovascular disease in clinical practice: A randomized, open-label, parallel-group, multicenter study (DISCOVERY Alpha study). Curr Ther Res Clin Exp (2006) 0.77
Baseline diabetes as a way to predict CV outcomes in a lipid-modifying trial: a meta-analysis of 330,376 patients from 47 landmark studies. Cardiovasc Diabetol (2015) 0.77
The many roles of statins in ischemic stroke. Curr Neuropharmacol (2014) 0.77
Accelerated decline in renal function after acute myocardial infarction in patients with high low-density lipoprotein-cholesterol to high-density lipoprotein-cholesterol ratio. Heart Vessels (2013) 0.76
Should a statin be prescribed to every patient with heart failure? Heart Fail Rev (2007) 0.76
Who should receive a statin drug to lower cardiovascular risk? Does the drug and the dose of the drug matter? Vasc Health Risk Manag (2006) 0.75
Beneficial effects of statins on the kidney. J Clin Pathol (2004) 0.75
Can combining different risk interventions into a single formulation contribute to improved cardiovascular disease risk reduction? The single pill of amlodipine/atorvastatin. Vasc Health Risk Manag (2007) 0.75
All cholesterol-lowering interventions are expected to reduce stroke: Confirmatory data from IMPROVE-IT. Data Brief (2016) 0.75
Unmet need in the hyperlipidaemia population with high risk of cardiovascular disease: a targeted literature review of observational studies. BMC Cardiovasc Disord (2016) 0.75
Comparison of the efficacy and safety of intensive-dose and standard-dose statin treatment for stroke prevention: A meta-analysis. Medicine (Baltimore) (2016) 0.75
Efficacy and tolerability of two different formulations of atorvastatin in Korean patients with hypercholesterolemia: a multicenter, prospective, randomized clinical trial. Drug Des Devel Ther (2017) 0.75
Efficacy, safety and tolerability of atorvastatin in dyslipidemic subjects with advanced (non-nephrotic) and endstage chronic renal failure. Clin Exp Nephrol (2006) 0.75
Is There an Ideal Low-Density Lipoprotein Cholesterol Level? Confusion regarding Lipid Guidelines, Low-Density Lipoprotein Cholesterol Targets, and Medical Management. Int J Angiol (2016) 0.75
Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care (2002) 1.73
Long-term follow-up of patients with acute hypertriglyceridemia-induced pancreatitis. J Clin Gastroenterol (2002) 1.53
Effect of statin treatment on renal function and serum uric acid levels and their relation to vascular events in patients with coronary heart disease and metabolic syndrome: a subgroup analysis of the GREek Atorvastatin and Coronary heart disease Evaluation (GREACE) Study. Nephrol Dial Transplant (2006) 1.24
Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study. Am J Kidney Dis (2004) 1.11
Awareness, treatment and control of the metabolic syndrome and its components: a multicentre Greek study. Hellenic J Cardiol (2006) 1.02
Comparison of four definitions of the metabolic syndrome in a Greek (Mediterranean) population. Curr Med Res Opin (2010) 1.01
Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study. Curr Med Res Opin (2004) 0.97
Early benefit from structured care with atorvastatin in patients with coronary heart disease and diabetes mellitus. Angiology (2003) 0.89
Statins and renal function in patients with diabetes mellitus. Curr Med Res Opin (2003) 0.89
Effect of atorvastatin on high density lipoprotein cholesterol and its relationship with coronary events: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin (2004) 0.88
Pathogenesis of osteoporosis in liver cirrhosis. Hepatogastroenterology (2006) 0.87
Targeting vascular risk in patients with metabolic syndrome but without diabetes. Metabolism (2005) 0.87
Atorvastatin decreases triacylglycerol-associated risk of vascular events in coronary heart disease patients. Lipids (2007) 0.82
Statin-Induced Increase in HDL-C and Renal Function in Coronary Heart Disease Patients. Open Cardiovasc Med J (2007) 0.82
Attaining United Kingdom-European Atherosclerosis Society low-density lipoprotein cholesterol guideline target values in the Greek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin (2002) 0.81
Long-term treatment effect of atorvastatin on aortic stiffness in hypercholesterolaemic patients. Curr Med Res Opin (2003) 0.80
Effects of statin treatment in men and women with stable coronary heart disease: a subgroup analysis of the GREACE Study. Curr Med Res Opin (2008) 0.80
Atorvastatin versus four statin-fibrate combinations in patients with familial combined hyperlipidaemia. J Cardiovasc Risk (2002) 0.77
Long-term treatment with atorvastatin in adolescent males with heterozygous familial hypercholesterolemia. Atherosclerosis (2002) 0.77
Relationship between LDL-C and non-HDL-C levels and clinical outcome in the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) Study. Curr Med Res Opin (2004) 0.76
Non-high density lipoprotein cholesterol and coronary events during long-term statin treatment. Atherosclerosis (2003) 0.76
Effect of statins and aspirin alone and in combination on clinical outcome in dyslipidaemic patients with coronary heart disease. A subgroup analysis of the GREACE study. Platelets (2005) 0.75